Cycloferon for Post-exposure Prophylaxis of Acute Respiratory Viral Infections and Influenza
Status:
Recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
Influenza and other acute respiratory viral infections remain practically uncontrollable
diseases due to the high variability of the antigenic structure of influenza viruses and the
heterogeneity of pathogens of acute respiratory infections. Therefore, for the prevention and
treatment of influenza, acute respiratory viral infections and herpes infections, it is
relevant to develop drugs - immunomodulators that mobilize the reserves of nonspecific and
specific immune systems and enhance the effects of these systems against the pathogens. The
drug CYCLOFERON, 150 mg, enteric-coated tablets, contains the active substance meglumine
acridone acetate, which is an interferon inducer. Interferons are the most important system
of innate immunity, which has antiviral and immunomodulatory effects, and can protect the
body from infection with a virus, and in case of infection, fight the causative agent of the
disease. The planned clinical trial of the efficacy and safety of the drug CYCLOFERON in the
dosage form of a tablet will study its ability to prevent influenza and other respiratory
viral infections in adults who have already had close contact with patients with manifest
disease.
Phase:
Phase 3
Details
Lead Sponsor:
POLYSAN Scientific & Technological Pharmaceutical Company